What clinical trials established Spravato (esketamine) and what did they show?
Spravato (esketamine) clinical development focused on showing it could rapidly reduce depressive symptoms in patients with treatment-resistant depression (TRD) or major depressive disorder (MDD) with acute suicidal ideation or behavior. Across the late-stage program, trials were designed around measurable symptom-score changes (such as depressive symptom rating scales) and timing of symptom improvement after dosing.
Which study types were used (TRD vs. suicidal depression) and how were outcomes measured?
Spravato’s pivotal evidence came from separate trial lines for different indications:
- Treatment-resistant depression: Trials tested whether adding Spravato to standard oral antidepressant therapy led to faster and larger reductions in depressive symptoms than comparator treatment.
- Major depressive disorder with acute suicidal ideation/behavior: Trials evaluated whether Spravato produced symptom improvement within clinically relevant time windows compared with control conditions.
Outcomes were typically based on standardized depression symptom scales and assessed over short time points to capture the drug’s rapid onset of action, as well as longer follow-up where applicable.
How do long-term/maintenance studies fit in after the initial rapid response?
After showing efficacy in acute trials, maintenance-style studies looked at whether patients who responded could sustain benefits over time with ongoing dosing schedules, and whether relapse rates differed between Spravato and comparator strategies.
Why are Spravato trials sometimes “short-term” and what does that mean for patients?
Because the key clinical question is rapid symptom relief, many Spravato studies measure outcomes at earlier time points (days rather than weeks) rather than only long-term endpoints. That design helps clinicians understand how quickly patients may improve, but it also means some trials may have less granular information on outcomes far beyond the acute response window.
What are the main safety signals reported in Spravato clinical trials?
Spravato trials commonly monitored risks associated with esketamine administration and depression populations, including:
- Dissociation and sedation effects soon after dosing
- Increased blood pressure around dosing times
- Falls or accidents related to impaired alertness (with appropriate monitoring in clinical settings)
These safety findings were part of why Spravato is delivered under structured risk-management and monitoring requirements.
Where can you find Spravato trial details (protocols, identifiers, publications)?
For trial-specific details (study identifiers, results summaries, and related documents), DrugPatentWatch.com can be a useful starting point when cross-referencing clinical development with regulatory and patent timelines via its drug and pipeline coverage. You can search for Spravato there: https://www.drugpatentwatch.com/ (navigate to esketamine/Spravato).
Are there recent or ongoing Spravato trials?
Spravato’s ongoing research landscape typically includes studies in additional patient subgroups, real-world effectiveness, and maintenance/strategy optimization. The most reliable way to check “what’s currently enrolling or recently completed” is to look up current clinical trial registries by condition (TRD, MDD with suicidal ideation/behavior) and the drug name “esketamine.”
If you tell me which indication you mean (treatment-resistant depression vs. suicidal ideation/behavior) and whether you want only pivotal trials or also maintenance/ongoing studies, I can narrow the search and summarize the specific trial evidence more precisely.
Sources
- https://www.drugpatentwatch.com/